103 related articles for article (PubMed ID: 2504834)
41. Comparative efficacy of 5 days of dirithromycin and 7 days of erythromycin in skin and soft tissue infections.
Wasilewski MM; Wilson MG; Sides GD; Stotka JL
J Antimicrob Chemother; 2000 Aug; 46(2):255-62. PubMed ID: 10933649
[TBL] [Abstract][Full Text] [Related]
42. A multicenter comparative study of cefotetan once daily and cefoxitin thrice daily for the treatment of infections of the skin and superficial soft tissue.
Geckler RW; Eng RH; Fabian TC; Echols RM; Jemsek JG; LeFrock JL; Mogabgab WC; Wilson SE
Am J Surg; 1988 May; 155(5A):91-5. PubMed ID: 3287976
[TBL] [Abstract][Full Text] [Related]
43. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen.
Bradsher RW; Snow RM
Am J Med; 1984 Oct; 77(4C):63-7. PubMed ID: 6093522
[TBL] [Abstract][Full Text] [Related]
44. Comparative efficacy and toxicity of roxithromycin and erythromycin ethylsuccinate in the treatment of streptococcal pharyngitis in adults.
Melcher GP; Hadfield TL; Gaines JK; Winn RE
J Antimicrob Chemother; 1988 Oct; 22(4):549-56. PubMed ID: 3060461
[TBL] [Abstract][Full Text] [Related]
45. Comparative double-blinded study between mupirocin and tetracycline ointments for treating skin infections.
Wong KS; Lim KB; Tham SN; Ling ML; Tan T
Singapore Med J; 1989 Aug; 30(4):380-3. PubMed ID: 2510312
[TBL] [Abstract][Full Text] [Related]
46. Cefadroxil in the treatment of skin and soft tissue infections.
Ballantyne F
J Antimicrob Chemother; 1982 Sep; 10 Suppl B():143-7. PubMed ID: 6754687
[No Abstract] [Full Text] [Related]
47. Systemic antimicrobial therapy in skin and skin structure infections: comparison of temafloxacin and ciprofloxacin.
Parish LC; Jungkind DL
Am J Med; 1991 Dec; 91(6A):115S-119S. PubMed ID: 1662880
[TBL] [Abstract][Full Text] [Related]
48. [Clinical evaluation of S6472 (prolonged action preparation of cefaclor) in the treatment of skin and soft tissue infections. A double blind comparison of S6472 and cefaclor].
Sakai K; Fujimoto M; Ueda T; Yura J; Shinagawa N; Ishikawa S; Tachi Y; Kobe A; Shibata Y; Doi S
Jpn J Antibiot; 1985 Oct; 38(10):2716-34. PubMed ID: 3908726
[TBL] [Abstract][Full Text] [Related]
49. An evaluation of tolerance of roxithromycin in adults.
Blanc F; D'Enfert J; Fiessinger S; Lenoir A; Renault M; Rezvani Y
J Antimicrob Chemother; 1987 Nov; 20 Suppl B():179-83. PubMed ID: 3429385
[TBL] [Abstract][Full Text] [Related]
50. Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections.
Lipsky BA; Miller B; Schwartz R; Henry DC; Nolan T; McCabe A; Magner DJ; Talbot GH
Clin Ther; 1999 Apr; 21(4):675-90. PubMed ID: 10363733
[TBL] [Abstract][Full Text] [Related]
51. Ciprofloxacin versus cefotaxime in skin and skin structure infections: a double-blind study.
Ramirez-Ronda C; Saavedra S
Chemioterapia; 1987 Jun; 6(2 Suppl):432-4. PubMed ID: 3334591
[No Abstract] [Full Text] [Related]
52. Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
Young RA; Gonzalez JP; Sorkin EM
Drugs; 1989 Jan; 37(1):8-41. PubMed ID: 2651088
[TBL] [Abstract][Full Text] [Related]
53. [Josamycin in bronchopulmonary and otorhinological diseases in pediatrics].
Kerschbaum H; Moritz AJ
Padiatr Padol; 1983; 18(4):403-8. PubMed ID: 6646791
[TBL] [Abstract][Full Text] [Related]
54. [Comparison of 3 antibiotics, cefaclor, josamycin and penicillin V in the treatment of acute throat infections. A multicenter study: 581 cases].
Elbaz P; Salord JC
Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):847-52. PubMed ID: 3309827
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
Ogrendik M
Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
[TBL] [Abstract][Full Text] [Related]
56. A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections.
Montero L
J Antimicrob Chemother; 1996 Jun; 37 Suppl C():125-31. PubMed ID: 8818853
[TBL] [Abstract][Full Text] [Related]
57. In vitro and in vivo antibacterial activity of 9,3"-Di-o-acetyl midecamycin (Mom), a new macrolide antibiotic.
Kawaharajo K; Sekizawa Y; Inoue M
J Antibiot (Tokyo); 1981 Apr; 34(4):436-42. PubMed ID: 6974163
[TBL] [Abstract][Full Text] [Related]
58. [Clinical use of josamycin in comparison with erythromycin in respiratory and urinary tract infections].
Lazzaro A; Vettori G; Bagozzi B
Clin Ter; 1985 Sep; 114(6):469-73. PubMed ID: 3905221
[No Abstract] [Full Text] [Related]
59. [Comparative study of TMS-19-Q and midecamycin for respiratory tract infection by double-blind method].
Kobayashi H; Nihei T; Takeda H; Kohno K; Saito A; Tomizawa M; Nakayama I; Hiraga Y; Kikuchi K; Yamamoto A
Kansenshogaku Zasshi; 1985 Feb; 59(2):201-26. PubMed ID: 3925037
[No Abstract] [Full Text] [Related]
60. Loracarbef (LY163892) versus cefaclor in the treatment of bacterial skin and skin-structure infections in an adult population.
McCarty J; Ruoff GE; Jacobson KD
Am J Med; 1992 Jun; 92(6A):80S-85S. PubMed ID: 1621751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
